Today (July 15), Johnson & Johnson announced via an internal email,Edward Zhou (Zhou Mintao) will assume the position of President of Johnson & Johnson Medical Technology, China Region, starting from July 25, 2024.，Report to Vishnu Karla, Chairman of Johnson & Johnson MedTech Asia Pacific. Meanwhile, Zhou Mintao will become one of the members of the Johnson & Johnson MedTech Asia Pacific leadership team.
Zhou Mintao, holding a Bachelor's degree in Biochemistry and a Master's degree in Business Administration from Fudan University, is highly reputed in the healthcare industry. Over the past 30 years, Zhou Mintao has gained profound recognition in the industry for his deep understanding of the healthcare policy environment, keen insight into patient and customer needs, firm commitment to talent development, and outstanding execution in achieving performance goals.
Since 1992, Zhou Mintao began his professional journey at Johnson & Johnson, initially as a sales representative in the consumer goods business, where he quickly demonstrated extraordinary potential and talent. Subsequently, he participated in Johnson & Johnson's international talent development program, and his experience in the UK further broadened his horizons and skills. After returning to China, he was promoted to General Manager of Johnson & Johnson's consumer goods business in Singapore. Later, he successfully led the acquisition and integration of the Da Bao brand in China, showcasing his strong capabilities in strategic planning and execution.
In 2015, Zhou Mintao's career entered a new phase as he moved to Johnson & Johnson Medical (China) Ltd., taking on the role of Vice President for the Ethicon Division’s surgical business. He was soon promoted to General Manager for the China region. During this period, Zhou Mintao not only drove continuous innovation in the business but also accelerated market expansion, optimized product lines, and introduced digital transformation. Particularly in the Suzhou Industrial Park, he led the localized smart manufacturing of advanced surgical products, significantly enhancing Johnson & Johnson Medical's competitiveness in the Chinese market. Under his leadership, the team achieved an impressive annual compound growth rate of 15%.
At the end of 2021, Zhou Mintao briefly left his position to join Danaher Corporation as President of the China Biotechnology Platform and Cytiva Greater China. He successfully led the integration with Pall Science, once again demonstrating his exceptional leadership in complex mergers and acquisitions.
In 2024, he will return to Johnson & Johnson and assume the position of President of MedTech China, Johnson & Johnson Medical Technologies China. In this critical role, he is expected to comprehensively lead Johnson & Johnson Medical Technologies China in advancing the company's long-term winning strategy, accelerating business growth, and actively fostering an innovative, patient-serving, and compliance-driven corporate culture.
As long as the enterprise keeps thriving, the talent pool will keep being refreshed.
In the past year, Johnson & Johnson has experienced several personnel changes. Two months ago, Will Song (Song Weiqun), Chairman of Johnson & Johnson China and President of Johnson & Johnson Medical Technology China, who had served the company for over 20 years, requested to resign. This news shocked the medical community at the time. A former senior executive of Johnson & Johnson China told reporters from relevant media: "In recent years, there have been significant personnel changes at Johnson & Johnson—global leaders, Asia-Pacific leaders, and R&D heads in the medical technology division have all been replaced." Let’s take a brief look at Johnson & Johnson's personnel changes in the past year:- In March 2023, an internal announcement by Johnson & Johnson China revealed that Chen Xi, General Manager of the Cardiovascular and Specialty Solutions Division (CSS) of Johnson & Johnson Medical Technologies in China, and Chen Min, General Manager of the Orthopedics Division in China, submitted their resignations to pursue external development opportunities. Subsequently, Johnson & Johnson Medical Technologies appointed Chen Chuhui and Han Wei to succeed the General Manager positions for the CSS and Orthopedics divisions, respectively.
- In April 2023, Wang Jinhe, Vice President of Operations and Professional Education at Johnson & Johnson Medical Technology China, submitted his resignation to pursue external opportunities.
- In October 2023, Johnson & Johnson Medical Technology announced the departure of its former Global Chairman and Executive Vice President, Ashley McEvoy, and appointed Tim Schmid, the former Asia-Pacific Chairman of Johnson & Johnson Medical Technology, as the new Global Chairman.
- On April 23, 2024, an internal email from Johnson & Johnson announced that Song Weiqun, Chairman of Johnson & Johnson China and President of Johnson & Johnson Medical Technology China, has submitted his resignation to the company after careful consideration, seeking external development opportunities.
- In May 2024, Johnson & Johnson Vision's Asia-Pacific President sent an email notification that Wang Liping, Vice President of Johnson & Johnson Vision in mainland China and Hong Kong, will step down after nearly 10 years of service with the company.
- At the same time, the company announced that Wang Jiyan, head of the cataract division of Johnson & Johnson's Vision Care in China, will step down. Jiyan has worked at Johnson & Johnson for 20 years and recently led the cataract product-related business in the Chinese market.
Infinite Potential, "Strong" and "Born"
Johnson & Johnson, founded in 1886, is one of the most comprehensive healthcare enterprises globally, with a broad range of operations spanning medical devices, pharmaceuticals, and consumer products. As one of the first foreign healthcare companies to enter the Chinese market, Johnson & Johnson Medical Technology entered China in 1994. Today, Johnson & Johnson Medical Technology has a team of over 5,000 people in China, with new-generation talent accounting for 85% of the workforce, and its headquarters is located in Shanghai.
For many years, Johnson & Johnson Medical Technology has upheld the spirit of open collaboration, accelerating the introduction of globally leading innovative medical products and solutions while working closely with various partners to expedite the implementation of innovative achievements and precisely meet the needs of local patients. The company actively collaborates with leading local innovators, utilizing technologies such as artificial intelligence, surgical robotics, and big data to accelerate the clinical application of digital surgical solutions.
In terms of financial performance, in the fiscal year 2023, Johnson & Johnson's global revenue recorded$85.2 billion，An increase of 6.5% over the previous year. Among them,Medical Technology BusinessWith strong performance in electrophysiology, contact lenses, wound management, and biosurgical products,Revenue for the year climbed to $30.4 billion, a year-on-year increase of 10.8%.。The latest financial report shows,Q1 2024Johnson & Johnson's global sales reached $21.4 billion, a year-on-year increase of 2.3%.Sales in the medical technology segment were $7.8 billion, an increase of 4.5%.The company forecasts its full-year sales to be in the range of $88.7 billion to $89.1 billion, surpassing the previous estimate of $88.2 billion to $89.0 billion.
Notably, in the face of global market volatility and intensifying industry competition, multinational healthcare companies are accelerating strategic adjustments and transformation to enhance their market competitiveness. Against this backdrop, Johnson & Johnson is actively responding to the reform of China's healthcare system by exploring new business models. Given China's rapid advancements in digital technology, Johnson & Johnson has adopted a forward-looking approach, driving digital innovation and expediting its transformation. Particularly noteworthy is the fact that China is the only market outside the U.S. where Johnson & Johnson has established R&D facilities across all its business sectors, underscoring the company’s high regard and long-term commitment to the Chinese market.
With the return of Zhou Mintao as President of Johnson & Johnson Medical Technology in China, Johnson & Johnson is standing at a new starting point, ready to embrace future challenges and opportunities. We look forward to Zhou Mintao infusing new vitality into Johnson & Johnson Medical Technology with his extensive experience and outstanding leadership skills, helping the company achieve deeper development in the medical technology field.
▲Source: Medical Device Innovation Network▲Reproduction without permission is prohibited.And can be reprinted after 24 hours！Disclaimer: This article is intended solely for the purpose of information transmission and is for reference only. It does not constitute any advice on investment or treatment. Please exercise caution in distinguishing the information. If it involves issues related to the content, copyright, and other aspects of the work, to protect the rights and interests of both parties, please contact us and we will handle it immediately.. If any platform reprints this article, it must take responsibility for the content of the article itself. The Medical Device Innovation Network is not responsible for any issues arising from secondary dissemination after reprinting.
